login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ZYMEWORKS INC (ZYME) Stock News
USA
- NASDAQ:ZYME -
US98985Y1082
-
Common Stock
17.93
USD
-0.39 (-2.13%)
Last: 10/21/2025, 6:54:08 PM
17.93
USD
0 (0%)
After Hours:
10/21/2025, 6:54:08 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ZYME Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Zymeworks Inc.
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
6 days ago - By: Zymeworks Inc.
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
3 months ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
7 days ago - By: Benzinga
- Mentions:
APP
COHR
ALB
PPG
...
Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
8 days ago - By: Zymeworks Inc.
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
8 days ago - By: Zymeworks Inc.
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
13 days ago - By: Zymeworks Inc.
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
13 days ago - By: Zymeworks Inc.
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
2 months ago - By: Stocktwits
- Mentions:
VFMO
IWMW
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
2 months ago - By: Zymeworks Inc.
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
2 months ago - By: Zymeworks Inc.
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
2 months ago - By: Zymeworks Inc.
Zymeworks Announces Participation in Upcoming Investor Conferences
2 months ago - By: Zymeworks Inc.
Zymeworks Announces Participation in Upcoming Investor Conferences
2 months ago - By: Zacks Investment Research
- Mentions:
CRMD
KOD
ALVO
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
2 months ago - By: Zacks Investment Research
- Mentions:
CRMD
IMVT
ALVO
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
2 months ago - By: Zacks Investment Research
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2 months ago - By: Zymeworks Inc.
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
2 months ago - By: Zymeworks Inc.
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
3 months ago - By: Zacks Investment Research
- Mentions:
BRTX
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
3 months ago - By: Zymeworks Inc.
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
3 months ago - By: Zymeworks Inc.
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
3 months ago - By: Zymeworks Inc.
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
3 months ago - By: Zymeworks Inc.
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
3 months ago - By: Zymeworks Inc.
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
3 months ago - By: Zymeworks Inc.
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
4 months ago - By: Zacks Investment Research
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
5 months ago - By: Stocktwits
- Mentions:
IWM
VTI
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
5 months ago - By: Zymeworks Inc.
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
5 months ago - By: Zymeworks Inc.
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
5 months ago - By: Zymeworks Inc.
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
Please enable JavaScript to continue using this application.